ALD-102Sol-001 Enrolling

Alopecia Areata Study (6 Months)


Treatment: Injection Age: 18 to 55 years


Who Can Participate?

Males and females aged between 18 to 55 with SALT score < 95 alopecia areata may participate.

Inclusion Criteria

  • be aged between 18 and 55 years
  • have a current episode of hair loss of > 6 months but < 5 years
  • have no known history of significant regrowth or hair loss during the last 6 months

weigh 50kg (110lbs) or more

Participant Information

  • Participate and receive study treatment at no cost
  • Regular visits with study doctors who specialise in treating alopecia areata (12 visits)
  • Will receive both the study drug and placebo in two treatment areas
  • Reimbursement for study-related expenses may be provided

How Long Will The Study Last For Each Participant?

  • 28 weeks

Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: April 17, 2025

Official Title

A Phase 1B/2A, Randomized, Double-blind, Placebo-controlled, Intraindividual Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

ClinicalTrials.gov ID

NCT06826196

Sponsor

Aldena Therapeutics

Study Description

  • Brief Summary:

    The goal of this first-in-human clinical trial is to learn if ALD-102 Solution is safe and well tolerated following injections in the scalp in subjects with alopecia areata. The study will also learn about the effect of ALD-102 on hair regrowth in treatment areas. The researchers will compare the effects of ALD-102 Solution (drug) to placebo (saline solution that contains no drug). Study participants will have two treatment areas selected on the scalp and will receive randomly ALD-102 Solution (drug) at one area and or placebo (saline solution) at the other area once every 4 weeks for a treatment period of 8 weeks.

  • Condition or Disease:

    Alopecia Areata (AA)

  • Intervention/Treatment:

    Drug: Placebo Drug: ALD-102
  • Phase:

    PHASE 1, PHASE 2

  • Ages Eligible for Study:

    18 Years to 55 Years (ADULT)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Alopecia Areata

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content